ChemicalBook >> CAS DataBase List >>R428

R428

CAS No.
1037624-75-1
Chemical Name:
R428
Synonyms
R428;CS-1130;BGB-324;EOS-62006;Bemcentinib;R428 (BGB324);BGB324 (R428);R428 USP/EP/BP;BGB-324, CPDB1725;Bemcentinib Crude
CBNumber:
CB42621146
Molecular Formula:
C30H34N8
Molecular Weight:
506.64
MDL Number:
MFCD21608463
MOL File:
1037624-75-1.mol
Last updated:2023-09-26 20:09:08

R428 Properties

Melting point >211°C (dec.)
Boiling point 799.6±70.0 °C(Predicted)
Density 1.41±0.1 g/cm3(Predicted)
storage temp. -20°C
solubility Soluble in DMSO (up to at least 25 mg/ml)
pka 10.34±0.20(Predicted)
form Yellow powder.
color Yellow
Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
FDA UNII 0ICW2LX8AS

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
NFPA 704
0
2 0

R428 price More Price(30)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 21523 R428 ≥98% 1037624-75-1 1mg $68 2024-03-01 Buy
Cayman Chemical 21523 R428 ≥98% 1037624-75-1 10mg $601 2024-03-01 Buy
Cayman Chemical 21523 R428 ≥98% 1037624-75-1 25mg $1002 2024-03-01 Buy
TRC R060020 R428 1037624-75-1 1mg $50 2021-12-16 Buy
ApexBio Technology A8329 R428 1037624-75-1 1mg $65 2021-12-16 Buy
Product number Packaging Price Buy
21523 1mg $68 Buy
21523 10mg $601 Buy
21523 25mg $1002 Buy
R060020 1mg $50 Buy
A8329 1mg $65 Buy

R428 Chemical Properties,Uses,Production

Description

R428 (bemcentinib, BGB324), a selective small-molecule inhibitor of AXL, is currently being evaluated in phase II trials for the treatment of non-small-cell lung cancer (NSCLC) and acute myelocytic leukemia (AML). It has been found to induce apoptosis in cancer cells and to block tumor spread in models of metastatic breast cancer. The therapeutic potential of R428 has also been demonstrated in highly invasive esophageal adenocarcinoma cells and in ESCC cells.
R428 is a selective, small molecule inhibitor of Axl that blocks its catalytic and precancerous activities. R428 treatment reduced Axl-induced AKT phosphorylation, cancer cell invasion, angiogenesis, and the production of pro-inflammatory cytokines. It also reduced the expression of the cytokine granulocyte macrophage colony-stimulating factor and Snail in a dosage-dependent manner. Interestingly,using R428 to inhibit Axl-mediated cellular and molecular functions during cisplatin treatments achieved an enhanced suppression of liver metastases. Axl knockdowns in RAC cell lines reduced migration, invasion, and in vivo engraftment, accompanied by a downregulation in the activity of the Ral GTPase proteins (RalA and RalB). Similar effects were obtained using an A428 inhibitor. Blocking Axl functions also abrogated the phosphorylation of ERBB2 (Her-2/neu) at the Tyr877 residue, which reveals the cross-functional effects of R428 on different receptor signaling axes.
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)

Uses

R 428 is an AXL tyrosine kinase inhibitor shown to be used as an anti-cancer agent.

target

Axl

References

1) Holland?et al.?(2010),?R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer;?Cancer Res.?70?1544 2) Fleuren?et al.?(2014),?The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma;?Oncotarget?5?12753 3) Xu?et al.?(2014),?Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma;?Biochem. Biophys. Res. Commun.?454?566 4) Ben-Batalla?et al.?(2017),?Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia;?Clin. Cancer Res.?23?2289 5) Lin?et al.?(2017),?Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer;?Oncotarget?8?41064 6) Guo?et al.?(2017),?Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models;?Oncotarget?8?89761 7) Ludwig?et al.?(2018),?Small-Molecule Inhibition of Axl Targets Tumor Immune

91-13-4
1037624-75-1
Synthesis of R428 from 1,2-Bis(bromomethyl)benzene

R428 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 161)Suppliers
Supplier Tel Email Country ProdList Advantage
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32480 60
Hangzhou MolCore BioPharmatech Co.,Ltd.
+86-057181025280; +8617767106207 sales@molcore.com China 49739 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578 sales@hbmojin.com China 12456 58
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714 fandachem@gmail.com China 9348 55
Speranza Chemical Co., Ltd.
+86-86-075521030354 +8618688942810 sophieliu@speranzachem.com China 723 55
Jinan Carbotang Biotech Co.,Ltd.
+8615866703830 figo.gao@foxmail.com China 6992 58
BOC Sciences
+1-631-485-4226 inquiry@bocsci.com United States 19553 58
career henan chemical co
+86-0371-86658258 15093356674; factory@coreychem.com China 29826 58
Neostar United (Changzhou) Industrial Co., Ltd.
+86-519-519-85557386 marketing1@neostarunited.com China 8349 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177 peter@yan-xi.com China 5993 58

View Lastest Price from R428 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
R428 pictures 2023-09-26 R428
1037624-75-1
US $0.00 / KG 1KG 99% 50000KG/month Hebei Mojin Biotechnology Co., Ltd
R428 pictures 2023-09-06 R428
1037624-75-1
US $0.00-0.00 / KG 1KG 99% 500000kg Hebei Guanlang Biotechnology Co., Ltd.
R428; R428 (BGB324) pictures 2020-01-08 R428; R428 (BGB324)
1037624-75-1
US $0.01 / KG 1KG 98%; 99% 1kg;10kg; 25kg Career Henan Chemical Co
  • R428 pictures
  • R428
    1037624-75-1
  • US $0.00 / KG
  • 99%
  • Hebei Mojin Biotechnology Co., Ltd
  • R428 pictures
  • R428
    1037624-75-1
  • US $0.00-0.00 / KG
  • 99%
  • Hebei Guanlang Biotechnology Co., Ltd.

R428 Spectrum

(S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine BGB-324 BGB-324, CPDB1725 (S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8 R428 R428 (BGB324) 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-[(7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl]-1H-1,2,4-triazole-3,5-diamine BGB324(R428,Bemcentinib) 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine R428-(R) (R428-P1) CS-1130 Bemcentinib(R428,BGB324) R-428; R 428;BGB-324;BGB 324 BEMCENTINIB (R428) 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-[(7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl]- R428 USP/EP/BP Bemcentinib intermediate EOS-62006 Bemcentinib BGB324 (R428) R428, 98%, a potent and selective inhibitor of Axl Bemcentinib BGB-324 R428 (S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-[7-(1-pyrrolidinyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine Bemcentinib Crude R-428 (BEMCENTINIB) 1037624-75-1 C30H34N8 C31H35N7 Inhibitors APIs API